HoneyNaps Expands AI Clinical Trial Analytics as CRO
BOSTON, July 27, 2026 HoneyNaps has officially registered as a Contract Research Organization (CRO) with the Korea National Enterprise...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON, July 27, 2026 HoneyNaps has officially registered as a Contract Research Organization (CRO) with the Korea National Enterprise...
MONTREAL, Canada / SEATTLE, Washington, July 12, 2026 HDT Bio Corp. has launched a major Canadian clinical development initiative...
TOKYO, Japan / CAMBRIDGE, Massachusetts, USA, July 12, 2026 Eisai Co., Ltd. and Biogen Inc. have announced new clinical...
BRIDGEWATER, New Jersey, USA / CAESAREA, Israel, July 9, 2026 Theranica has announced a major reimbursement milestone for Nerivio®,...
GENEVA, Switzerland, July 9, 2026 MindMaze Therapeutics Holding SA has announced its support for a University of Pittsburgh clinical...
PROVIDENCE, Rhode Island, July 6, 2026 Nabsys 2.0, LLC, a pioneer in electronic genome mapping (EGM) technology, has appointed...
COLLEGE STATION, Texas, July 6, 2026 Matica Biotechnology, Inc. (Matica Bio) has entered into a strategic partnership with VaxDome...
NEW YORK, July 6, 2026 DarioHealth Corp. has announced a significant expansion of its digital health platform through a...
HAMBURG & MUNICH, March 5, 2026 Daiichi Sankyo Europe and GAIA, a global pioneer in evidence-based digital therapeutics, have...
GENEVA, Switzerland — December 23, 2025 — MindMaze Therapeutics, a commercial-stage innovator in evidence-based, precision digital treatments for neurological...
